

Soledad Retamozo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7216995/publications.pdf>

Version: 2024-02-01

46
papers

1,416
citations

471509

17
h-index

434195

31
g-index

47
all docs

47
docs citations

47
times ranked

1813
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 3-18.	0.9	307
2	Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 348-355.	0.9	149
3	Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 137-156.	3.0	118
4	Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1255-1271.	2.4	106
5	Monoclonal gammopathy related to Sjögren syndrome: A key marker of disease prognosis and outcomes. <i>Journal of Autoimmunity</i> , 2012, 39, 43-48.	6.5	70
6	Clinically-useful serum biomarkers for diagnosis and prognosis of sarcoidosis. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 391-405.	3.0	70
7	Life-Threatening Cryoglobulinemic Patients With Hepatitis C. <i>Medicine (United States)</i> , 2013, 92, 273-284.	1.0	69
8	Validation of the classification criteria for cryoglobulinaemic vasculitis. <i>Rheumatology</i> , 2014, 53, 2209-2213.	1.9	67
9	Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. <i>RMD Open</i> , 2019, 5, e001064.	3.8	53
10	Haemophagocytic syndrome and COVID-19. <i>Clinical Rheumatology</i> , 2021, 40, 1233-1244.	2.2	53
11	Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients. <i>Rheumatology</i> , 2016, 55, 1443-1451.	1.9	51
12	Prognostic markers of lymphoma development in primary Sjögren syndrome. <i>Lupus</i> , 2019, 28, 923-936.	1.6	51
13	Sarcoidosis: an update on current pharmacotherapy options and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2431-2448.	1.8	37
14	Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 686-92.	0.8	28
15	How are we treating our systemic patients with primary Sjögren syndrome? Analysis of 1120 patients. <i>International Immunopharmacology</i> , 2015, 27, 194-199.	3.8	25
16	Severe, life-threatening phenotype of primary Sjögren's syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry). <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 121-129.	0.8	21
17	SARS-CoV-2 infection in patients with systemic autoimmune diseases. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 676-687.	0.8	20
18	Diagnosis of Liver Involvement in Primary Sjögren Syndrome. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 1, 94-102.	1.4	19

#	ARTICLE	IF	CITATIONS
19	Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects. <i>Drugs</i> , 2016, 76, 1601-1623.	10.9	15
20	Cryoglobulinemic disease. <i>Oncology</i> , 2013, 27, 1098-1105, 1110-6.	0.5	15
21	Etiopathogenic Role of Surfactant Protein D in the Clinical and Immunological Expression of Primary Sjögren Syndrome. <i>Journal of Rheumatology</i> , 2015, 42, 111-118.	2.0	12
22	Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. <i>Rheumatology</i> , 2022, 62, 243-255.	1.9	12
23	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 166-174.	0.8	12
24	SARS-CoV-2 infection in patients with systemic autoimmune diseases. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 676-687.	0.8	8
25	An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2359-2371.	1.8	6
26	AB0542...Blocking the Human B Lymphocyte Stimulator Molecule (BLYS) Using A Monoclonal Antibody (Belimumab) in Systemic Lupus Erythematosus: First Results in Real-Life Spanish Patients with Refractory Disease (Biogears-Semi Registry). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 985.2-985.	0.9	5
27	Crioglobulinemia. <i>Medicina Clínica</i> , 2022, 158, 478-487.	0.6	5
28	Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. <i>Drugs and Aging</i> , 2021, 38, 265-284.	2.7	4
29	OPO211...Association between Systemic Activity and Lymphoma in Primary Sjogren Syndrome: Baseline Essdai Predictors in 921 Spanish Patients (GEAS-SS Registry). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 142.2-142.	0.9	3
30	OPO213...The Degree of Activity Measured with the EULAR-SS Disease Activity Index (ESSDAI) Strongly Correlated with Death in Patients with Primary Sjogren Syndrome (GEAS-SS REGISTRY). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 143.1-143.	0.9	1
31	SAT0206...Minimally-Invasive Technique for the Biopsy of Minor Salivary Glands: Searching for Systemic Infiltrative Diseases in Patients Presenting with SICCA Symptoms. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 664.2-664.	0.9	1
32	SAT0175...Results of the Classification Criteria for Cryoglobulinemic Vasculitis Validation Study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A640.2-A641.	0.9	0
33	THU0399...Systemic Amyloidosis as A Multi-Organ, Life-Threatening Disease: Predictive Baseline Factors Associated to Mortality in 570 Patients (Ramyd-Geas-Semi Registry). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 319.3-320.	0.9	0
34	THU0398...Adult Hemophagocytic Syndrome: Analysis of 50 Cases (Spanish National Registry Geas-Semi). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 319.2-319.	0.9	0
35	THU0298...Are Anti-La Antibodies A Potential Protection for Hepatitis C Virus Infection in Sjögren Syndrome? Analysis in 663 Patients. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 286.2-286.	0.9	0
36	THU0397...Clinical Presentation and Characterization of Neurosarcoidosis: Analysis in 719 Patients (Sarcogears-Semi Registry). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 319.1-319.	0.9	0

#	ARTICLE	IF	CITATIONS
37	THU0396â€¦.Igg4-Related Disease or Primary Sjogren Syndrome? Organ-Specific Involvement and Immunological Profile Are Clues in Differentiating Two Diseases with A Common Clinical Presentation. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 318.3-319.	0.9	0
38	AB1089â€¦.Diagnosis of Systemic Inflammatory Diseases in Patients with Fever Referred to A Quick Diagnosis Unit: Experience of A Third Level Teaching Hospital in Barcelona. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1161.3-1162.	0.9	0
39	THU0408â€¦.How we are Treating Our Systemic Patients with Primary SjÃ¶gren Syndrome? Analysis of 1120 Patients (GEAS-SS Spanish Registry). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 344.2-344.	0.9	0
40	OPO274â€¦.Cryoglobulinemic Vasculitis and Primary sjÃ¶gren's Syndrome are Independent Risk Factors for Lymphoma in a Large Worldwide Population of Patients with Positive Serum Cryoglobulins. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 175.3-176.	0.9	0
41	SAT0385â€¦.Multiple infection is independently related to death in adult patients with hemophagocytic syndrome: etiopathogenically-driven multivariate analysis in 151 patients. , 2018, , .		0
42	THU0665â€¦.Pharmacovigilance surveillance of autoimmune diseases induced by biological agents: a review of 16123 cases (AEBIOGEAS-SEMI REGISTRY). , 2018, , .		0
43	AB1266â€¦.Autoimmune diseases induced by biological agents used in patients with advanced cancer: a nationwide multicenter registry of cases diagnosed in daily practice (CBIOGEAS-SEMI). , 2018, , .		0
44	SAT0416â€¦.Life-threatening primary sjÃ¶gren syndrome: clinical characterisation and outcomes in 1535 patients (GEAS-SS REGISTRY). , 2018, , .		0
45	Post-COVID-19 syndrome in patients with primary SjÃ¶gren's syndrome after acute SARS-CoV-2 infection. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
46	Influence of the age at diagnosis in the disease expression of primary SjÃ¶gren syndrome. Analysis of 12,753 patients from the SjÃ¶gren Big Data Consortium.. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 133, 166-174.	0.8	0